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A widely adaptable approach to generate
integration-free iPSCs from non-invasively
acquired human somatic cells
Dear Editor,
Human pluripotent stem cells including human embryonic
stem cells (ESCs) and induced pluripotent stem cells (iPSCs)
are cells displaying abilities of unlimited self-renewal and dif-
ferentiation into any somatic cell type. These uniqueproperties
make them increasingly attractive for novel applications in
disease modeling, drug discovery, and cell therapy (Buganim
et al., 2014; Liu et al., 2011; Liu et al., 2012; Sanchez Alvarado
and Yamanaka, 2014). Moreover, iPSCs hold great potential
for personalized cell therapy as they avoid some of the ethical
concerns as well as the immunological rejection issues ascri-
bed to ESCs. To date, iPSCs can be generated from various
cell sources that range from commonly used skin ﬁbroblasts to
rarely employed blood cells, mostly through virus-based
reprogramming methods with different efﬁciencies (Patel and
Yang, 2010). However, the isolation of these original human
cells often involves an invasive sample acquisition procedure.
Therefore, human somatic cells that can be conveniently
obtained in a non-invasive manner, including human endo-
metrium cells (EMCs) and human urine-derived cells (UCs),
may represent more convenient and promising sources for the
generation of iPSCs. This is especially crucial for patients
hypersensitive to any invasive operation (i.e. patients with
Diabetes mellitus (DM) and patients with hemophilia). On the
other hand, non-integrative reprogrammingmethods including
thosemediatedbyepisomal vectors (Okitaetal., 2011),Sendai
virus vectors (Seki et al., 2012) andsmall chemicals (Houet al.,
2013; Lin et al., 2009), are increasingly regarded as superior
alternatives to viral approaches. Recently, an elegant study
has demonstrated that iPSCs could be established by an epi-
somal system comprised of miR-302–367 from human UCs
(Xue et al., 2013). Here we report on the generation of inte-
gration-free human endometrium-derived iPSCs (emiPSCs)
and urine-derived iPSCs (uiPSCs) by a modiﬁed episomal
reprogramming system. Subsequently, we show that these
iPSCs can robustly differentiate into several valuable lineage-
speciﬁc cell types, including pancreatic progenitor cells (PPs)
and neural stem cells (NSCs).
Healthy and patient donors at an age ranging from 8 to 83
were recruited with signed and approved consents by our
institutional committees. 1–3 mL menstrual blood or 200–500
mL urine was centrifuged and washed by phosphate-buf-
fered saline (PBS) containing Penicillin-Streptomycin, and
then cultured in mesenchymal cell medium and renal epi-
thelial cell medium respectively for 1–2 weeks. In total, we
established 5 EMC lines from healthy donors and 16 UC
lines from healthy individuals and type II DM patients. These
primary EMCs and UCs proliferate well and could be pas-
saged for at least 6 passages in culture. Next, two EMC lines
and two UC lines from healthy individuals and one UC line
from a DM patient were randomly chosen and subjected to
cellular reprogramming. A normal ﬁbroblast line isolated from
a 9-year old donor (Liu et al., 2011) was used as the
reprogramming control. Here, we utilized a modiﬁed system
by which integration-free iPSCs have been successfully
generated from ﬁbroblasts of a FANCA mutant Faconi ane-
mia (FA) patient (Liu et al., 2014; Seki et al., 2012). This
approach was proven to be robust as FA patient ﬁbroblasts
were reported to be refractory to somatic cell reprogramming
(Liu et al., 2014; Raya et al., 2009). We also proved that cells
reprogrammed through this strategy maintained genomic
integrity even in a compromised disease context, as FA
patient cells have a defective DNA repair system (Liu et al.,
2014; Raya et al., 2009). To initiate cell reprogramming, we
electroporated a cocktail of episomal vectors that encode for
human OCT4, SOX2, KLF4, LIN28, L-MYC, and a p53-
speciﬁc shRNA, into EMCs and UCs respectively. Sodium
butyrate was included in the medium to facilitate cell repro-
gramming-associated epigenetic remodeling (Liu et al.,
2014; Mali et al., 2010). After seeding on top of mouse
embryonic ﬁbroblast (MEF) feeders, small iPSC-like colonies
appeared around 10 days after electroporation for all
selected lines. Typical iPSC colonies with human ESC
morphology were ready for picking and expanding at around
day 20 (Fig. 1A). All resulting iPSC lines demonstrated typ-
ical ESC features, including a high nucleus/cytoplasma ratio,
positive alkaline phosphatase (AP) activity, expression of
pluripotency markers OCT4, SOX2, and NANOG, as well as
demethylation of the OCT4 promoter (Fig. 1A–D). These
cells were stably cultured on MEF or Matrigel for more than
20 passages, without acquiring any karyotypic aberrance
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(Fig. 1E). Additionally, quantitative RT-PCR (RT-qPCR)
analysis showed no residual episomal vector element in the
established iPSC lines (Fig. 1F).
We further examined the in vitro and in vivo differentiation
potentials of the generated iPSCs. The in vitro spontaneous
differentiation potential of iPSCs was investigated by
embryoid body (EB)-based differentiation assays. As shown
in Fig. 1G, iPSCs effectively differentiated into TUJ1 (ecto-
derm), SMA (mesoderm), as well as FOXA2 and ALB
(endoderm)-positive cells upon spontaneous differentiation.
Furthermore, after injection into immune-deﬁcient NOD/
SCID mice, iPSCs were able to develop into teratomas
composed of cells from all three germ-layers marked by
SMA, AFP, PDX1, and Nestin expressions (Fig. 1H).
Next, we investigated the potency of the iPSCs in directed
cell differentiations. PPs and NSCs were chosen because of
their value in potential applications. In order to generate PPs,
iPSCs were ﬁrstly treated with a combination of activin A and
Wnt3a to initiate the deﬁnitive endoderm cell (DE) differenti-
ation, a step resulting in 95% endodermal progenitors co-
expressing FOXA2 and SOX17 (Fig. 1I and 1J). After treating
the endodermal progenitors with Retinoic acid, FGF10,
Noggin, and Cyclopamine-KAAD, we obtained a highly pure
population of PPs positive for the pancreatic progenitor
marker PDX1 (Fig. 1I and 1J). As anticipated, these PPs also
expressed NKX6.1 and NGN3. An upregulation of insulin
gene (INS) expression at transcriptional level was also
observed (Fig. 1I and 1J). Additionally, we differentiated
iPSCs toward NSCs by treatment with a chemically deﬁned
medium comprising of hLIF, SB431542, CHIR99021, Com-
pound E, and dorsomorphin (Liu et al., 2012). These resulting
NSCs expressed typical neural progenitor markers SOX2,
PAX6, Musashi, and Nestin (Fig. 1K). As a characteristic
feature of neural progenitor cells, these cells were able to
efﬁciently differentiate into MAP2 and TUJ1-positive neurons
when exposed to a differentiation medium containing ascor-
bic acid, dbcAMP, BDNF and GDNF for 14 days (Fig. 1K).
In summary, we demonstrated here that integration-free
iPSCs can be efﬁciently and consistently obtained from non-
invasively acquired human EMCs and UCs, even in a
defective disease context (i.e. type II DM) (Fig. 1L). Given
the fact that a similar strategy has been proven to be
effective in reprograming diseased somatic cells inherently
resistant to the regular cell reprogramming procedure (Liu
et al., 2014), we speculate that this methodology could be
universally adaptable for various applications. The autolo-
gous PP and NSC derivatives generated from emiPSCs and
uiPSCs could be further subjected to animal transplantation
studies (Sui et al., 2013; Zhang et al., 2009), and even
potentially be applied to human regenerative medicine set-
tings. The robustness and non-invasive nature of our system
to generate iPSCs from human samples may enormously
fuel the application of human iPSCs towards novel cell
therapy as well as applications in disease modeling and drug
discovery in the near future.
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Figure 1. Establishment and characterization of emiPSCs
and uiPSCs. (A) Cellular morphology and AP staining of
emiPSCs and uiPSCs generated from human EMCs and UCs.
(B) RT-qPCR analysis of endogenous pluripotency gene
expression in indicated lines. H9 human ESCs and GM00038
human ﬁbroblasts were used as positive and negative controls,
respectively. (C) DNA methylation analysis of the OCT4
promoter in the L-UC and L-uiPSC lines. The positions of the
CpG dinucleotides relevant with the OCT4 transcription start
site are present. (D) Immunoﬂuorescence analysis of pluripo-
tency markers OCT4, NANOG, and SOX2 in L-uiPSCs. Nuclear
DNA was stained with Hoechst 33258. (E) G-band analysis of
L-uiPSCs showing a normal karyotype. (F) Copy number
quantiﬁcation of the episomal vector element EBNA1 in
indicated iPSC lines. H9 human ESCs were employed as a
negative control, and the P-UCs 4 days (P-UC D4) after
electroporation with the episomal reprograming factors were
used as a positive control. (G–H) Spontaneous EB differenti-
ation in vitro (G) and teratoma analysis in vivo (H) verify the
differentiation potentials of iPSCs towards endodermal, meso-
dermal, and ectodermal tissues. Scale bar, 75 μm for the
teratoma analysis. (I–J) Immunoﬂuorescence analysis (I) and
RT-qPCR (J) demonstrate the up-regulation of FOXA2, SOX17
in DE; and up-regulation of PDX1, NKX6.1, NGN3, and INS in
PPs. (K) Immunoﬂuorescence analysis shows NSCs generated
from iPSCs express speciﬁc makers SOX2, Musashi, Nestin,
and PAX6; and neurons generated from iPSCs express
neuronal makers MAP2 and TUJ1. All scale bars represent
25 μm unless otherwise speciﬁed. (L) Schematic presentation
of establishing integration-free emiPSCs and uiPSCs and
generating their PP and NSC derivatives in vitro.
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have signed written informed consent for donating EMCs and UCs
for somatic cell reprogramming and iPSC study.
Zhichao Ding1, Lina Sui1, Ruotong Ren1, Yanjun Liu2, Xiuling
Xu1, Lina Fu1, Ruijun Bai1,3, Tingting Yuan1, Ying Hao4,
Weiqi Zhang1, Huize Pan1, Wensu Liu1, Han Yu1,
Concepcion Rodriguez Esteban7, Xiaobing Yu5, Ze Yang5,
Jian Li5, Xiaomin Wang6, Juan Carlos Izpisua Belmonte7,
Guang-Hui Liu1,6,8&, Fei Yi9&, Jing Qu4&
1 National Laboratory of Biomacromolecules, Institute of Biophysics,
University of the Chinese Academy of Sciences, Chinese Acad-
emy of Sciences, Beijing 100101, China
2 Department of Endocrinology, 306th Hospital of PLA, Beijing
100101, China
3 Science and Development, Xtem, Foshan 528000, China
4 State Key Laboratory of Reproductive Biology, Institute of Zoology,
Chinese Academy of Sciences, Beijing 100101, China
5 Beijing Hospital of the Ministry of Health, Beijing 100073, China
6 Beijing Institute for Brain Disorders, Beijing 100069, China
7 Gene Expression Laboratory, Salk Institute for Biological Studies,
10010 North Torrey Pines Road, La Jolla, CA 92037, USA
8 Center for Molecular and Translational Medicine, Beijing 100101,
China
9 Department of Molecular and Cellular Physiology, Stanford
University School of Medicine, Stanford, CA 94305, USA
& Correspondence: ghliu@ibp.ac.cn (G.-H. Liu), fyi@stanford.edu
(F. Yi), qujing@ioz.ac.cn (J. Qu)
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and
the source are credited.
REFERENCES
Buganim Y, Markoulaki S, van Wietmarschen N, Hoke H, Wu T,
Ganz K, Akhtar-Zaidi B, He YP, Abraham BJ, Porubsky D et al
(2014) The developmental potential of iPSCs is greatly inﬂu-
enced by reprogramming factor selection. Cell stem cell 15:295–
309
Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, Zhao T, Ye J, Yang W, Liu
K et al (2013) Pluripotent stem cells induced from mouse somatic
cells by small-molecule compounds. Science 341:651–654
Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, Lin X,
Hahm HS, Hao E, Hayek A et al (2009) A chemical platform for
improved induction of human iPSCs. Nat methods 6:805–808
Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, Yang SL, Panopoulos AD,
Suzuki K, Kurian L, Walsh C et al (2011) Recapitulation of
premature ageing with iPSCs from Hutchinson-Gilford progeria
syndrome. Nature 472:221–225
Liu GH,Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S,
Zhang W et al (2012) Progressive degeneration of human neural
stem cells caused by pathogenic LRRK2. Nature 491:603–607
Liu GH, Suzuki K, Li M, Qu J, Montserrat N, Tarantino C, Gu Y, Yi F,
Xu X, Zhang W et al (2014) Modelling Fanconi anemia patho-
genesis and therapeutics using integration-free patient-derived
iPSCs. Nat Commun 5:4330
Mali P, Chou BK, Yen J, Ye Z, Zou J, Dowey S, Brodsky RA, Ohm
JE, Yu W, Baylin SB et al (2010) Butyrate greatly enhances
derivation of human induced pluripotent stem cells by promoting
epigenetic remodeling and the expression of pluripotency-asso-
ciated genes. Stem cells 28:713–720
Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S,
Hong H, Nakagawa M, Tanabe K, Tezuka K et al (2011) A more
efﬁcient method to generate integration-free human iPS cells. Nat
methods 8:409–412
Patel M, Yang S (2010) Advances in reprogramming somatic cells to
induced pluripotent stem cells. Stem cell rev 6:367–380
Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S,
Barrero MJ, Consiglio A, Castella M, Rio P, Sleep E et al (2009)
Disease-corrected haematopoietic progenitors from Fanconi
anaemia induced pluripotent stem cells. Nature 460:53–59
Sanchez Alvarado A, Yamanaka S (2014) Rethinking differentiation:
stem cells, regeneration, and plasticity. Cell 157:110–119
Seki T, Yuasa S, Fukuda K (2012) Generation of induced pluripotent
stem cells from a small amount of human peripheral blood using
a combination of activated T cells and Sendai virus. Nat Protoc
7:718–728
Sui L, Liu GH, Izpisua Belmonte JC (2013) hESC-derived pancreatic
progenitors. Cell res 23:592–594
Xue Y, Cai X, Wang L, Liao B, Zhang H, Shan Y, Chen Q, Zhou T, Li
X, Hou J et al (2013) Generating a non-integrating human
induced pluripotent stem cell bank from urine-derived cells. PloS
One 8:e70573
Zhang D, Jiang W, Liu M, Sui X, Yin X, Chen S, Shi Y, Deng H (2009)
Highly efﬁcient differentiation of human ES cells and iPS cells into
mature pancreatic insulin-producing cells. Cell res 19:429–438
Zhichao Ding, Lina Sui, Ruotong Ren, and Yanjun Liu have
contributed equally to this work
Electronic supplementary material The online version of this
article (doi:10.1007/s13238-014-0117-1) contains supplementary
material, which is available to authorized users.
Generation of integration-free iPSCs from non-invasively acquired human somatic cells LETTER
© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn 389
P
ro
te
in
&
C
e
ll
